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Donor specific antibodyUNOS implemented a new Kidney Allocation System (New KAS) on December 4, 2014 with a primary goal
of increasing equity to organ transplant for patients that were immunologically or socially disadvantaged
by the previous allocation system (Previous KAS) that prioritized long wait times. We examined the
effects of the New KAS on patients transplanted from the UCLA deceased donor waitlist during the first
year and compared to the last year of the Previous KAS. The total number of deceased donor kidney trans-
plants was increased in the New KAS as compared to the Previous KAS (178 vs 148). Transplant of regraft
patients and of highly sensitized patients with cPRAP 99% was significantly increased in the New KAS
(New KAS vs Previous KAS, 29.8% vs 11.5%, p 6 0.0001, and 26.4% vs 2.7%, p 6 0.0001, respectively). In
the New KAS, the percentage of patient’s receiving allografts imported from outside our local area was
also significantly increased (34.8% vs 15.5%, p < 0.0001). In the New KAS, 59.7% and 48.3% of imported
organs were allocated to very highly sensitized (P99% cPRA) or re-graft patients, respectively, as com-
pared to 8.7% and 8.7% during the Previous KAS (p < 0.001). Recipients and donors with age differences
exceeding 15 years were decreased in the New KAS as compared to the Previous KAS (36.5 vs 48.7%,
p60.032). There was a 40.1% reduction in transplant to patients in the 65+ age group in the New KAS
(p 6 0.025). The percentage of patients transplanted with preformed donor specific antibody (DSA)
was similar in the New as compared to the Previous KAS (19.7% vs 15.5%) and, patients were transplanted
with a range of 1–3 preformed DSA of weak to moderate strength. Cold ischemic time was significantly
increased over all organs, and in patients transplanted with preformed DSA during the New as compared
to the Previous KAS (17.5 vs 19.1 h and 17.2 vs 22.2, p < 0.04 and p < 0.03, respectively). Episodes of
delayed graft function and the number of biopsies for cause were similar between the New and the
Previous KAS. However, there were more events of biopsy proven antibody mediated rejection in patients
transplanted since the start of the New KAS. The data show that the New KAS is working at the center
level as designed to better age match recipients and donors and to increase transplantation of very highly
sensitized patients through broader sharing.
 2016 The Author(s). Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
In December 2014, UNOS initiated a new Kidney Allocation Sys-
tem (New KAS) to replace the previous allocation system (Previous
KAS) established in 1987 [1,2]. The New KAS is designed to
increase the median lifespan and allograft-year survival in trans-
plant recipients and to improve transplant to patients who are
42 M.J. Hickey et al. / Human Immunology 78 (2017) 41–48socially or immunologically disadvantaged by shortfalls of the Pre-
vious KAS that prioritized longer wait times [3,4]. The New KAS is
predicted to improve access to transplants for patients who were
disadvantaged by broad sensitization to HLA antigens or by
delayed referral to transplant centers, and to limit age mismatch
between expected recipient and donor kidney longevity thereby
also reducing allograft discard rate.
Several core components have been built into the New KAS to
achieve these goals [1]. First, patients and donors are risk stratified
according to two new calculated parameters. The Estimated Post-
Transplant Survival (EPTS) score ranks patients based on age, dial-
ysis time, diabetes status and primary or regraft status. The Kidney
Donor Profile Index (KDPI) ranks donors based on multiple param-
eters of age, size, clinical status and donation after circulatory
death status. Lower percentage EPTS and KDPI are correlated with
improved post-transplant survival. In the New KAS, ‘‘longevity
matching” between patients and donors is achieved by prioritizing
patients with EPTS 6 20% to receive kidneys from donors with
KDPI 6 20%. The second component is the use of a sliding scale
from which points are awarded based on calculated panel reactive
antibody (cPRA) prioritizing candidates with high cPRA. A third
component broadens sharing for patients with a cPRAP 99%. Pedi-
atric candidates in the New KAS maintain priority over adult can-
didates to receive local offers from donors with KDPI < 35%. To
increase transplant of blood type B candidates, eligibility for trans-
plant with A2/A2B donors is now implemented with the New KAS.
Finally, wait time is awarded to recipients based on time spent on
dialysis prior to being registered to the waitlist—a component that
was piloted in our local area prior to the start of the New KAS.
Simulated projections of the New KAS indicated a potential for
increase in transplant of candidates in the 18–49 age range, for
those of blood type B, and those with a cPRAP 99%, and fewer
transplants for candidates > 50 years old and those of blood type
A [1]. In addition, allocation to those hardest to transplant, that
is, very highly sensitized patients, would be improved by allowing
regional and national sharing for candidates with cPRAP 99% and
regional sharing of kidneys from donors with a KDPIP 85% [1].
These projections have been largely substantiated at the
national level in the monitoring reports presented by UNOS/OPTN
[5–8]. Nationally, an increase in transplantation of African Ameri-
cans is also reported. Lacking from the national data, however, is
analysis of short term outcomes in patients transplanted with pre-
formed donor specific antibody (DSA). Patients that are very highly
sensitized with a cPRA > 99%make up6% of the UCLA active wait-
list for deceased donor renal transplantation and represent those
that are at highest risk for delayed graft function (DGF) and rejec-
tion. Evaluating the New KAS at the center level is also important
to assure that the quality of a national system is met at the local
level. In this report, we present the data from the first year of the
New KAS in comparison to the Previous KAS at the center level.2. Materials and methods
2.1. Demographics
Patients who underwent deceased donor kidney transplant at
UCLA during the first year of the New KAS (12/4/2014 to
12/4/2015) were compared to those transplanted during the same
time period in the previous year (Previous KAS, 12/4/2013 to
12/3/2014). For all patients, sex, age at time of transplant, blood
group, cPRA, regraft status and EPTS scores were gathered from
UNOS data. Additional demographic information was collected by
reviewing the patient’s medical records including race, induction
therapy, immunosuppression, presence of DSA, DGF, biopsy results,
donor/recipient HLA-A, B, DR, DQ mismatch and graft loss.Deceased donor KDPI, local or regional/national import status
and cold ischemic time were also determined from UNOS data. This
study was approved by the UCLA institutional review board.2.2. Antibody screening
Pretransplant, patients were screened for antibodies to HLA
Class I and II using Lifecodes Flow Luminex PRA (Life Codes, Nor-
cross, GA). Negative sera were screened annually. Sera identified
as positive were then tested by Single Antigen Bead assay using
the One Lambda LABScreen kit (One Lambda, ThermoFisher, Wal-
tham, MA) and antibody reactivity greater than or equal to 1000
MFI were considered positive [9]. HLA antibody strength and speci-
ficity were tested at least annually by single antigen in patients
found to be sensitized to HLA antigens. Post transplant, patients
are stratified into immune monitoring protocols based on the pres-
ence or absence of preformed DSA at the time of transplant. Post
transplant single antigen bead testing is also performed at suspi-
cion of rejection.2.3. HLA typing and crossmatch
Patient and donor HLA typing was performed by molecular
methods as previously described [9]. Complement dependent T
and B cell cytotoxicity crossmatches and T and B cell flow cytomet-
ric crossmatches were performed on all patients prior to trans-
plant. In some cases, prior to performing the CDC or flow
crossmatches, sera were treated with DTT to remove IgM, or T
and B cells were incubated with pronase to remove Fc receptors
and CD20 [10,11]. The positive threshold for a T or B flow cross-
match with or without pronase treatment is 50 or 120 median
channel shift (MCS), respectively [9].2.4. Immunosuppression
Throughout the duration of the study, induction was primarily
solumedrol and basiliximab or anti-thymocyte globulin. The use
of IVIG to augment immunosuppression at the time of transplant
is used in most patients with DSA that is identified within one year
of transplant (current). For patients with historic DSA, the use of
IVIG at the time of transplant is at the discretion of the attending
nephrologist. Maintenance immunosuppression for patients trans-
planted during both the New and Previous KAS primarily consisted
of triple therapy with tacrolimus, mycophenolate mofetil (MMF)
and steroids.2.5. Diagnosis of rejection
Renal biopsies are not performed by protocol, but for cause on
suspicion of allograft rejection. Rejection was characterized by
the Banff classification [12].2.6. Statistical methods
Statistical analyses were performed using Stata software ver-
sion 13 (StataCorp, College Station, TX). Comparisons for categori-
cal variables such as age group, cPRA group, blood type and race
were analyzed by Fisher’s exact test. Continuous variables such
as cold ischemia time and DSA strength were compared using
the Wilcoxon rank sum test. All tests were two-sided. P-
values 6 0.05 were considered significant.
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Fig. 1. Age of patients transplanted during Previous and New KAS. a) Patients
transplanted during the New and Previous KAS grouped according to age (years).
The percentage of patients transplanted in the age 65+ group is significantly
reduced in the New KAS as compared to the Previous KAS (p < 0.02). b) Percentage
of transplants with donor:recipient age difference >15 years in the New and
Previous KAS.
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3.1. Patient demographics
During the first year of the New KAS 178 deceased donor kidney
transplants were performed at UCLA while 148 transplants were
performed during the last year of the Previous KAS (Table 1). Of
these, there was one combined kidney/pancreas transplant during
the Previous KAS, and two were performed during the New KAS.
There were no significant differences between patients trans-
planted in the New KAS or the Previous KAS with respect to gender,
race, blood group, or number of HLA-A, B, DR zero mismatch trans-
plants (Table 1). In contrast to national data presented by OPTN/
UNOS the percentage of African American candidates transplanted
was not significantly affected at our center during the New KAS [8].
Furthermore, no donor blood group A2/A2B to recipient blood
group B transplants were performed.
The New KAS has made significant impact with respect to the
age of transplant recipients in comparison to the Previous KAS.
The median age of patients transplanted during the New KAS at
our center was 51.0 years (range 2–78 years) that is significantly
lower than the median age of patients transplanted during the Pre-
vious KAS (56.0 years, range 2–80 years, p < 0.01, Table 1). The
reduction in median age of transplant recipients is further evi-
denced when the patients are subdivided based on age group
(Fig. 1a). The data show that there is a significant reduction in
the percentage of patients transplanted in the 65+ age group in
the New KAS, while transplants to patients in the 18–64 age range
were increased (p < 0.03; Fig. 1a, Table 1). Although the numbers
are small, transplant of pediatric patients in the 0–17 age range
were similar our center in the New KAS as compared to the Previ-
ous KAS, 6.2% vs 4.1%, respectively (Fig. 1a).
The New KAS prioritizes the transplant of adult patients with an
EPTS 6 20% to receive allografts from donors with KDPI 6 20% [1].
During the New KAS, 11.3% of transplanted adult patients with an
EPTS 6 20% received an allograft from a donor with KDPI 6 20%
(Table 1). Our center’s data suggest that longevity matching is
improved since the start of the New KAS. When evaluating allTable 1
Transplant Demographics.
Previous KAS New KAS p-value
n (%) n (%)
Total number of transplants 148 178
Sex 89 60.1 109 61.2 0.46
Age in years, median (range) 56 (2–80) 51 (2–78) 0.01
Age in years
0–64 110 74.3 151 84.8 0.01
65+ 38 25.7 27 15.2
Race
White 21 14.2 35 19.7 0.18
Black 32 21.6 33 19.9
Hispanic 60 40.5 81 45.5
Asian 31 21 22 12.4
Other 4 2.7 7 3.9
Blood Group
A 50 33.8 54 30.3 0.34
B 20 13.5 28 15.7
O 65 43.9 88 49.4
AB 13 8.8 8 4.5
Donor A2/A2B to Recipient B – – 0 0
% KDPI, median (range) 47.5 (1–100) 50.5 (1–96) 0.95
KDPI 6 20% to EPTS < 20% – – 20 11.3
Re-transplant 17 11.5 53 29.8 0.0001
% cPRAP 98% 4 2.7 47 26.4 0.0001
Zero A B DR Mismatch 18 12.2 11 6.2 0.05
Cold time, hr, Av (range) 17.5 (4.0–40.0) 19.1 (5.3–42.9) 0.04
Graft Loss 3 2.0 1 0.6
44 M.J. Hickey et al. / Human Immunology 78 (2017) 41–48transplants, we find that there is a significant reduction in the per-
centage of recipient-donor pairs with an age difference > 15 years
in the New KAS as compared to the Previous KAS (36.5% vs
48.6%, p = 0.03, Fig. 1b).
There is a significant shift in the New KAS toward transplant of
patients who are very highly sensitized with cRPAP 98%
(p < 0.0001, Table 1). Overall, 29.2% of patients transplanted at
our center during the first year of the New KAS had a cPRA of
95–100%, and 23.6% were very highly sensitized with a cPRA of
99–100% (Fig. 2a). This is in striking contrast to the Previous KAS
where only 2.0% of patients transplanted were very highly sensi-
tized (p < 0.0001, Fig. 2a). Consequently, there was a measurable
decrease in transplant of patients with a cPRA in the 0–79% range.
Transplant of patients with a cPRA of 99–100% peaked at the start
of the New KAS at 30.0%, and is longitudinally declining (Fig. 2b).
Allocation of organs to patients receiving their second or third
transplant is significantly increased at our center in the New KAS
as compared to the Previous KAS (p < 0.0001, Table 1). The percent-
age of re-transplanted patients was increased nearly 3-fold in the
New KAS as compared to the Previous KAS (29.8% vs 11.5%).
A core component of the new UNOS KAS is broader sharing of
organs for patients that are very highly sensitized with a
cPRAP 99% [1]. There was a 2-fold increase in patients trans-
planted with kidneys that were imported from outside of our ser-
vice area in the New KAS as compared to the Previous KAS (34.8%
vs 15.5%, p = 0.0001, Table 2).0 
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Fig. 2. cPRA of patients transplanted during the Previous and New KAS. a) Patients
transplanted during the New and Previous KAS grouped according to cPRA. There is
a significant shift toward transplant of very highly sensitized patients in the New
KAS as compared to the Previous KAS (p < 0.0001). b) Quarterly, the percentage of
patients transplanted with cPRAP 99% in the Previous and New KAS. Transplant of
very highly sensitized patients peaked at the beginning of the New KAS (indicated
by horizontal line) and is decreasing with time.Characteristics of transplants with non-locally obtained organs
were further evaluated (Table 2). During the New KAS our center
saw 59.7% of imported kidneys allocated to very highly sensitized
patients (cPRAP 99%, n = 37, Table 2), the majority of whom were
also re-transplant patients (n = 30, 48.3%; Table 2). This is in con-
trast to the Previous KAS when only 8.7% (n = 2) imported allo-
grafts were allocated to patients with cPRAP 99% both of whom
were re-transplant patients (p < 0.0001 and p < 0.001, respec-
tively). The KDPI of imported organs allocated to patients in the
Previous and New KAS according to patient cPRA was also evalu-
ated (Table 2). In the New KAS, the average KDPI of imported
organs allocated to patients with a cPRA of 0–98% was 62.1% (range
1–93%) and of grafts allocated to very highly sensitized patients
was 41.8% (range 1–90%). During both the New and Previous
KAS, allografts with a KDPI > 85% were primarily allocated to recip-
ients with cPRA < 99%. Importantly, during the study period, all
imported organs were transplanted to the patient for whom they
were initially accepted.
3.2. Patients transplanted with preformed donor specific antibody
Studying the effects of the New KAS at the center level allows
for evaluation of the presence of preformed donor specific anti-
body. The percentage of patients transplanted with preformed
DSA in the New and Previous KAS was similar (19.7 vs 15.5;
Table 3). Preformed antibody was classified either as current,
meaning that it was present in the most recent serum tested by
single antigen bead assay within one year prior to transplant, or
as historic, meaning that it was absent in the most current serum
yet present at some time during the patient’s history. Among
patients transplanted with preformed DSA, the DSA was present
in the patient’s serum at the time of transplant (current and cur-
rent/historic) in 37.1% (n = 13) patients transplanted during the
New KAS and in 65.2% (n = 15) patients transplanted during the
Previous KAS. In addition, 71.4% (n = 25) patients in the New KAS
were transplanted with historic DSA (historic and current/historic)
in comparison to only 43.5% (n = 10) in the previous (Table 3). In
the New and Previous KAS, patients were transplanted with a
range of 1–3 DSA (Table 3). The range of strengths of preformed
DSA present within one year prior to transplant is shown in
Fig. 3. The median DSA strength between patients transplanted
in the New and Previous KAS was similar (Previous KAS, median
2414 MFI [range: 1073–5805 MFI] and New KAS, median 3590
MFI [range: 1408 MFI-16353 MFI]), and statistical analysis shows
that there is no distinction between the two groups (p = 0.3,
Fig. 3) [13].
The use of immunosuppressive induction therapy augmented
with IVIG was similar in this subset of patients during the New
and Previous KAS (51.4% vs 60.9%, Table 3). Three patients in the
New KAS with current preformed DSA had weak positive cross-
matches in comparison to only one patient in the Previous KAS
(Table 4). Two of the three positive crossmatches in the New KAS
were for re-transplant patients with 100% cPRA that received kid-
neys imported from outside of our local area.
3.3. Cold ischemic time
A significant difference in cold ischemic time was noted overall
on allografts transplanted during the New KAS as compared to the
Previous KAS (19.1 vs 17.5 h, p = 0.04, Table 1). The cold ischemic
time on organs imported from outside of our local area was similar
in the Previous and New KAS (22.5 vs 22.6 h, Table 2). The cold
time on imported allografts transplanted to very highly sensitized
patients with cPRAP 99–100% was also similar in the Previous
and New KAS (21.9 vs 21.7 h, Table 2). However, when evaluating
the subset of patients transplanted with preformed DSA there is
Table 3
Transplants With Preformed DSA.
Previous KAS New KAS p-value
n = 148 n = 178
n (%) n (%)
Preformed DSA 23 15.5 35 19.7 0.38
Current 13 10
Historic 8 22
Current/Historic 2 3
Class I 14 19
Class II 8 10
Class I/II 1 6
Preformed DSA, Av (range) 1.3 (1–3) 1.2 (1–2)
cPRAP 99% 1 4.4 20 57.1 0.0001
Cold time, hr, Av (range) 17.2 (4.0–31.9) 22.2 (7.1–42.7) 0.03
Import 0 0.0 19 54.2 0.0001
%KDPI, Av (range) 38.5 (4–90) 43.5 (1–90) 0.45
KDPIP 85% (n) 1 1
IVIG 14 60.9 20 51.4 0.72
DGF 8 34.7 14 40.0 0.40
Biopsy for cause 11 47.8 12 34.3 0.41
ATN 7 8
ACR 3 0
AMR 1 3
Other 0 1
Table 2
Transplants with Import Allografts (Recipients and Donors).
Previous KAS New KAS p-value
n = 148 n = 178
n (%) 23 (15.5) 62 (34.8) 0.0001
Cold time, hr, Av (range) 22.5 (15.1–29.9) 22.6 (7.1–42.9) 0.93
cPRA 0–98% cPRA 99–100% cPRA 0–98% cPRA 99–100%
n (%) 21 (91.3) 2 (8.7) 25 (40.3) 37 (59.7) 0.0001 *
Re-transplant, n (%) 3 (13.0) 2 (8.7) 2 (3.2) 30 (48.3) 0.001*
%KDPI, Av (range) 58.5 (23–93) 22 62.1 (1–93) 41.8 (1–90) 0.27*
KDPIP 85% (n) 3 0 6 1
Cold time, hr, Av (range) 22.5 (15.1–29.9) 21.9 (19.3–24.6) 23.9 (12.8–42.9) 21.7 (7.1–42.7) 0.97*
* p value refers to comparison between patients with cPRA 99–100% in the Previous and New KAS.
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Fig. 3. Strength (MFI) of preformed DSA in sera tested within one year of transplant.
Box and whisker plot shows range of preformed DSA strengths in the most current
pre-transplant sera measured by single antigen bead test. Horizontal line indicates
median (Previous KAS 2414 MFI, New KAS 3590 MFI). Box indicates upper and
lower quartiles with whiskers showing the adjacent upper and lower values. One
outlier is shown.
Table 4
Positive crossmatches in patients with current preformed DSA.
Previous KAS New KAS
1 T Flow: 49 MCS T Flow: 18 MCS
B Flow: 124 MCS B Flow: 157 MCS
DSA: A1 3220 MFI, A24 2435 MFI DSA: DP10 4420 MFI
2 – T Flow: 53 MCS
B Flow: 103 MCS
DSA: A3 1650 MFI, C7 2037 MFI
3 – T Flow: 18 MCS
B Flow: 124 MCS
DSA: A11 2075 MFI
M.J. Hickey et al. / Human Immunology 78 (2017) 41–48 45significantly increased cold ischemic time on organs from the New
KAS as compared to the Previous KAS (22.7 vs 17.2 h, p < 0.03) as
more than half of these grafts were imported from outside of ourlocal area while none of the grafts were imported during the Previ-
ous KAS for this subset of patients (Table 3).3.4. Short term outcomes in recipients with preformed DSA
Preformed DSA, cold ischemia time and donor quality are risk
factors for delayed graft function (DGF) and rejection [14]. Defined
as the need for dialysis during the first 7 days post-transplant, DGF
was assessed in patients transplanted with preformed DSA during
the New and Previous KAS. Although cold ischemic time was
longer for allografts transplanted to patients with preformed DSA
during the New KAS a similar percentage of patients experienced
46 M.J. Hickey et al. / Human Immunology 78 (2017) 41–48DGF during the New and Previous KAS (40.0% vs 34.7%, p = 0.40,
Table 3).
In patients transplanted with preformed DSA, there was no sig-
nificant difference in the percentage of patients that underwent a
biopsy for cause during the New and Previous KAS (Table 3). The
majority of histopathological results were consistent with acute
tubular necrosis (ATN). Three patients in this subset were found
to have acute cellular rejection (ACR) during the Previous KAS.
Although not statistically significant, there were more cases of
biopsy proven antibody mediated rejection (AMR) during the
New KAS as compared to the Previous KAS. The immunologic char-
acteristics of AMR+ patients transplanted with preformed DSA are
shown in Table 5. In total, 3 of the 4 patients were transplanted
with a preformed DSA that was present historically, but not within
one year prior to the transplant. One patient was transplanted dur-
ing the New KAS with a DSA present within 4 months of the trans-
plant date (Patient 4, current, DPB1*04:02, 7235 MFI). All 4 of these
patients had negative crossmatches at the time of transplant. Only
one patient had immunosuppression augmented with IVIG. Patient
4 was not treated with IVIG at the time of transplant as at that time
the donor’s DP typing was not known. All four cases of AMR
occurred within one year post transplant, and three of the four
occurred within 60 days of transplant. In all four patients, HLA
DSA correlated to the AMR positive biopsy, and two of four patients
had an expansion of HLA DSA with more DSA specificities present
than previously noted. At the time of AMR, three patients were
treated with plasmapheresis (PP) and IVIG or thymoglobulin. One
patient was treated with IVIG and steroids and one patient
received rituximab. There have been no events of graft loss in these
four patients.3.5. Graft loss
In patients transplanted during the Previous KAS, 3 allografts
were lost (Table 1). In two of these, the graft was lost during the
first week post transplant, followed by re-listing with the previous
wait time and re-transplant during the New KAS. The third
patient’s graft failed approximately 1.5 years post transplant and
the patient is currently relisted. One graft was lost from patients
transplanted during the New KAS. The patient, transplanted with
an organ isolated from a local donor with 23 h of cold ischemic
time, was non-sensitized and experienced DGF and BK viremia
post transplant. The graft failed after approximately 3 months,
and the patient was relisted with their previous wait time and aTable 5
Immunologic characteristics of AMR positive patients transplanted with preformed DSA.
Patient
No.
KAS Current/
Historic
Preformed
DSA
Immunosuppression AMR
Antigen Days po
transpla
1 Previous Historic A24 Solumedrol/Thymo/
IVIG
12
A68
2 New Historic DP2 Solumedrol/Thymo/
PP
54
3 New Historic B37 Solumedrol/Thymo 310
4 New Current DP402 Solumedrol/
Basiliximab
10
1. Patient also had recurrent FSGS.cPRA of 100%. The patient was retransplanted during the study per-
iod with an organ imported from outside of our local area.4. Discussion
The data from our single center experience in the first year of
the New KAS show that the national UNOS Kidney Allocation Sys-
tem is working at the center level as designed to increase equity in
access to renal transplantation. We evaluated the effects of major
core components of the New KAS 1) broader sharing of organs
for patients that are very highly sensitized, 2) patient:allograft
longevity matching and 3) increased equity to candidates histori-
cally disadvantaged such as African Americans and other minori-
ties. The data from our single center study also allows for
analysis of allograft transplants to higher risk patients with pre-
formed DSA.
Our findings, show that transplantation of very highly sensi-
tized patients is increased more than 10-fold in the New KAS
(Table 1, Fig. 1a) with nearly 60% of imported organs allocated to
these patients (Table 2). This is in contrast to the Previous KAS,
where the few imported organs were primarily allocated to
patients with low cPRA. The 10-fold increase observed at our cen-
ter is above the 4.5-fold increase observed nationally [8]. At our
center, and nationally, transplant of very highly sensitized patents
increased sharply during the first few weeks of the New KAS
(Fig. 2b). Interestingly, at our center, the initial spike in transplant
of very highly sensitized patents rose to 30% of transplants,
nearly double what was observed nationally. This so called ‘‘bolus
effect” is hypothesized to be sustained by transplant of patients
with common haplotypes leaving those with uncommon or
homozygous typings perpetually listed. While nationally, the rate
of transplantation of these patients appears to have stabilized at
12%, the rate at our center continues to decline (Fig. 2b). At equi-
librium, the New KAS offers a platform to study patient character-
istics that lead to transplant vs death on the waitlist.
Similar to national data, we show improved longevity matching
with the New KAS as recipients of allografts with patient:donor age
differences > 15 years was significantly reduced (Fig. 1b) [8]. Fur-
thermore, 11.3% of patients with EPTS < 20% received an allograft
from a donor with KDPI < 20% (Table 1). With respect to transplant
recipient age, we observed a significant, 40%, reduction in trans-
plant of patients >65 years that is greater than the 20% reduction
observed nationally (Table 1, Fig. 1a) [8]. The apparent enhanced
effects of the New KAS at our center, discussed here and above,
may correlate to the small number of transplants at our center,DSA AMR Therapy
st
nt
Rejection type Antigen MFI
Acute AMR, C4d+ A24 10235 PP  5 days, IVIG
A68 5386
B35 10928
B39 10304
Acute AMR, C4d+ 1 B64 1214 PP 3 per week, IVIG,
Ritux
DR1 2954
DP402 4573
DP2 3878
AMR, C4d-, Suspicious
for ACR
B37 6059 IVIG, Steroids
AMR, C4d- DP402 3846 PP  5 days, Thymo
M.J. Hickey et al. / Human Immunology 78 (2017) 41–48 47as compared to national numbers. Effects outside of the New KAS,
such as center specific practice, may also contribute. Transplant of
pediatric patients is similar at our center in the Previous and New
KAS study periods (Fig. 1a) [8]. Although, nationally, after one year
in the New KAS transplant of pediatric patients is similar to the
Previous KAS, transplant of pediatrics in our region (Region 5) is
reduced likely to the number of very highly sensitized patients
listed for transplant and is hypothesized to recover after equilib-
rium is reached.
The data from our center are in contrast with parameters of the
national data that report a statistically significant rise in transplant
of African American patients and patients with blood type B.
Nationally, transplant of African Americans increased significantly
by 17% in the New KAS [8]. This is likely a result of increased list-
ing of this population of patients in preparation for the start of the
new system, and of the core component that awards wait time
points for time spent on dialysis prior to waitlist registration [1].
At our center, however, the percentage of whites and minorities
transplanted was not different between the Previous and New
KAS (Table 1). African Americans listed at our center for deceased
donor renal transplant from June 2014 through March 2015, a per-
iod bridging the time when patients may have been added to the
waitlist in preparation for the start of the New KAS, was stable at
14% indicating referral of this ethnic group to our transplant cen-
ter was not affected by the New KAS. Furthermore, our local area
piloted the change in wait time from days since registration to
the waitlist to days on dialysis. Therefore, at the start of the New
KAS, we did not observe a bolus of patients transplanted due only
to long dialysis time.
The national data also report a significant increase in transplant
of blood type B recipients as a result of eligibility for A2/A2B donors
[8]. However, this is due to the very modest total number of kidney
transplants that have occurred nationally in this demographic
(n = 109) since the start of the New KAS. At our center, no blood
group B recipients are listed as eligible for a A2/A2B kidney dona-
tion. Successful deceased donor transplant of patients across ABO
blood group requires considerable additional clinical management
pre- and post-transplant [15]. The percentage of B kidneys in our
local donor pool is too few to justify the cost of this pre-
management and may explain the low percentage of patients
nationally consented for this option [7].
Similar to national data, we show a significant increase in
cold ischemic time over all organs since the start of the New
KAS (Table 1) [8]. Cold ischemic time on organs transplanted
to patients with preformed DSA during the New KAS was signif-
icantly increased as the majority of these were imported from
outside of our local area (Table 3). Despite the increase in cold
ischemic time, however, the percentage of patients transplanted
with preformed DSA and experiencing DGF was similar between
the New and Previous KAS (Table 3). Although there was no sig-
nificant difference in the percentage of patients transplanted
with preformed DSA during the New and Previous KAS there
was a trend toward an increase in transplant across preformed
DSA that were historic (Table 3, historic and current/historic,
Previous KAS 43.5%, New KAS 71.4%). In the New KAS, these
patients also tended to be very highly sensitized and were recip-
ients of organs imported from outside our local area. While the
percentage of ‘‘for cause” biopsies in patients transplanted with
preformed DSA were similar (Table 3), there were more AMR
positive biopsies in patients transplanted during the New KAS
as compared to the Previous KAS (Tables 3 and 5). The immuno-
logic features of patients with AMR positive biopsies were
diverse with respect to DSA class and strength, proximity to
transplant, immune induction therapy, and histologic features
of AMR. Therapy at the time of AMR also differed, but included
plasmapheresis in three of the four cases.The success of the national KAS is due in large part to the
advancement of solid phase assays and the ability to identify and
block unacceptable antigens. With broader regional and national
sharing of organs for highly sensitized patients as a core compo-
nent of the New KAS, confidence in risk assessment by virtual
crossmatch is essential. Our laboratory, and others, have experi-
enced a significant increase in requests for virtual crossmatch since
the start of the New KAS resulting in extensive modifications to
staffing and laboratory workflow to accommodate the need. To
improve the speed and accuracy of virtual crossmatch case review
we also developed a computer program that assesses the patient’s
history of solid phase antibody tests for the presence of DSA prior
to Director’s review and risk assessment. This also allows for a
reduction in manual review, and increased documentation and
reporting to the electronic medical record. Our analysis indicates
that 15–20% of patients are transplanted with at least one DSA of
weak to moderate strength (1000–8000 MFI, Fig. 3). Virtual cross-
match prediction can be equivocal in the context of multiple weak
DSA, or DSA near the unacceptable threshold [16]. However, only
three very weak positive crossmatches were observed since the
start of the New KAS (Table 4), and importantly, all organs
imported during the New KAS were transplanted to the intended
initial recipient. These data indicate that our strategies for identi-
fying and blocking unacceptable antigens and assessing the pres-
ence/strength of donor specific antibody are satisfactory.
Still, it is important to consider the potential long term effects
on graft outcome in transplanting patients across a strong DSA,
even in the context of a negative crossmatch and augmented
immunosuppression [17–19]. In the New KAS, one patient with
100% cPRA was transplanted with a DSA to DPB1*04:01 at 16363
MFI (Fig. 3), and a negative flow crossmatch, with an organ
imported from outside of our local area. At the time of transplant,
the patient was given immunosuppression with antithymocyte
globulin augmented with a three-day course of IVIG. The patient
experienced DGF during the first week post transplant. While the
DSA to DPB1*04:01 was below the positive threshold by single
antigen bead test 37 days post transplant, a weak DSA to B44
was identified. After two additional treatments with IVIG the
patient is negative for HLA DSA. The patient has not had cause
for biopsy during the short study period.
A total of four patients transplanted during the New KAS had
only one DSA in serum current to the transplant that was to a DP
antigen (Fig. 3). Two of these were to DPB1*04:01 (16353 MFI,
Fig. 3 and discussed above, and 7235 MFI, Fig. 3 and Table 5,
Patient 4), one was to DPB1*02:01 (6169 MFI, Fig. 3), and the last
was to DPB1*10:01 (4420 MFI, Fig. 3 and Table 4). While, overall,
there was no significant difference in strength of DSA current to
the transplant in patients transplanted during the New and Previ-
ous KAS, three out four of these particular DSA exceeded the max-
imum strength of DSAs in the Previous KAS (Fig. 3, max 5805 MFI).
Three of these four patients were treated with immunosuppression
augmented with IVIG at the time of transplant. Cell surface expres-
sion of HLA DP is considered to be lower than expression of DR and
DQ antigens [20]. DPB1*04:01 and DBB1*02:01 also carry the 496 A
variant in the 30UTR that is associated with even lower cell surface
expression, potentially explaining the negative crossmatch in con-
text of these moderate/strong DSA [21,22]. In contrast, the DSA to
DPB1*10:01, carrying the 496 G variant, resulted in weak a positive
crossmatch (Table 4). Since DP antigens can be entered as unac-
ceptable on the UNOS waitlist it is important to consider antigen
expression and DSA strength when evaluating the risk of trans-
plant. Certainly, to improve patient care and avoid disadvantaging
patients with strong DP DSA, more data is needed relating DSA
strength to crossmatch results and graft outcome in patients trans-
planted with HLA DP antibodies. In addition, as one of these four
transplants resulted in acute AMR (Table 4), long term outcomes
48 M.J. Hickey et al. / Human Immunology 78 (2017) 41–48must also be assessed when transplanting across a DSA to DP, or
antigen of another loci. Despite the lower expression of DP antigen
on the cell, transplantation across a single DSA to DP is not without
risk [18,19,23]. Furthermore, although transplanting patients with
preformed DSA with immunosuppression augmented with IVIG
results in significantly fewer rejection episodes it is not always
effective and acute AMR remains an issue [24–26].
The New KAS provides great opportunity to transplant higher
risk patients- those receiving their second or third transplant
who are very highly sensitized with long dialysis times- and will
result in fewer patients expiring while waitlisted on dialysis. How-
ever, if transplanting across DSA results in more rejections and ear-
lier graft loss, then the ultimate goal of the New KAS, to increase
graft and patient survival years will not be met. Longer term out-
come data to assess these effects with an appropriate comparator
group—very highly sensitized patients transplanted in the absence
of DSA—is essential.
The New KAS appears to be working at the center and national
levels to address shortfalls of the Previous KAS. Monitoring of
national policy at the center level is essential to assess the effect
on patient care and ensure quality is met. The New KAS prioritizes
transplant of hardest to transplant patients—those who are very
highly sensitized and likely to also have preformed DSA. Although
short term outcomes of DGF, biopsies for cause and graft loss were
similar between the New and Previous KAS at our center, long term
outcomes must be evaluated to determine if the goal of increasing
allograft and patient years is achieved through the New KAS.Funding
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